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Methods: We reviewed the records of the Taiwan Pediatric Renal Collaborative Study, a multi-
center database of Taiwanese children with CKD. Multivariate regression analysis was used to
identify the main factors associated with disease progression.
Results: A total of 382 children aged 1e18 years were included in the study (median age was
10.6 years; interquartile range: 6.4e13.8). There were 197 males (51.6%) and 185 females. CKD
Stage 1 was diagnosed in 159 children (41.6%), Stage 2 in 160 (41.9%), Stage 3 in 51 (13.4%), and
Stage 4 in 12 (3.1%). Fifty-six children (14.7%) experienced CKD progression. A multivariate
analysis for all patients indicated that the risk for disease progression was increased in childrenhave no conflicts of interest relevant to this article.
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Etiology and pediatric CKD progression 753with CKD secondary to a structural abnormality, genetic disease, anemia, elevated diastolic
blood pressure, or elevated blood urea nitrogen. Compared with children with Stage 1 CKD,
those with Stage 2 and Stage 4 CKD had decreased risk for CKD progression in this short-
term cohort follow-up.
Conclusion: CKD etiology affects disease progression. Careful monitoring and treatment of
anemia and elevated blood pressure in children with CKD may slow disease progression.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Chronic kidney disease (CKD) is characterized by decreased
renal function. CKD can be progressive and may ultimately
result in end-stage renal disease. To date, the majority of
research into CKD has focused on adults. Little information
is available about CKD in a pediatric population, particu-
larly for early-stage disease, despite the fact that CKD is
not uncommon in children (3.0e12.1 cases per million)1,2
and the incidence of pediatric CKD is increasing.3 This is
concerning not only because CKD can progress to end-stage
renal disease, but also because CKD in children can alter
nutrition and bone and mineral metabolism,4 thereby
affecting growth. It can also have a negative effect on the
quality of life of the afflicted children and their families.5,6
There are many differences in the etiology, progression,
and treatment of CKD in adults compared with that in chil-
dren,3 andwhatwe knowabout CKD in adultsmay not apply to
children. Additional information on CKD in children is needed
to improve diagnosis, maximize treatment, and potentially
slow the progression of the disease in this population.
Although studies have recently begun to examine the
epidemiology and clinical characteristics of pediatric
CKD,7e11 very little information has beenpublished describing
the factors associated with disease progression in children,8
and there are no data about the epidemiology and clinical
characteristics of East Asian children with CKD. As there are
ethnic differences in the incidence of end-stage renal dis-
ease,12 it is important to determine the epidemiology and
clinical characteristics of East Asian children with CKD.
We reviewed the Taiwan Pediatric Renal Collaborative
Study (TAPRC) database, which contains the records of
children with CKD treated at the major centers that serve
Taiwan. We present the patients’ demographic and clinical
characteristics, factors associated with disease progres-
sion, and data on CKD etiology. We analyzed children who
had CKD due to structural abnormalities of the genitouri-
nary tract or genetic diseases,13 and those who had CKD due
to nephritis and hemodynamic changes following previous
acute renal failure.Patients and methods
Study design
We conducted a retrospective review of the TAPRC central
database (Table S1). The study included Taiwanese children
aged 1e18 years who received treatment for CKD betweenJanuary 2009 and June 2012. The inclusion criteria were as
follows: study participants could not be older than 20 years
at follow-up (age at first visit was <17.5 years); they had to
have a diagnosis of broad-spectrum renal disease for more
than 3 months; they had to meet the criteria for categori-
zation in accordance with the staging system of the Kidney
Disease Outcomes Quality Initiative14; and the participants
had to have between 0.5 and 1.5 years of follow-up data
available in the database. Children aged 1e2 years were
eligible for enrollment despite the fact that the Kidney
Disease Outcomes Quality Initiative staging system is not
applicable to children <2 years of age.
Table S2 shows the differences between children who
were included in the study and those who were excluded. In
brief, children who were included tended to be older and to
have higher ages at the onset of disease, as well as higher
systolic blood pressure, height, weight, body mass index,
estimated glomerular filtration rate (eGFR), and hemoglo-
bin and hematocrit levels. In addition, a greater proportion
of study patients presented with proteinuria, autoimmune
disease, hyperlipidemia, or gout.
Patients not requiring drug therapy were followed once
every 6 months. Stable patients requiring continuous drug
therapy were followed every 3 months, as required by
Taiwan’s National Health Insurance system.
Renal function was assessed using the eGFR calculated
using the new Schwartz equation.15 An eGFR of <90 mL/
min/1.73 m2 or a CKD of >90 mL/min/1.73 m2 in the pres-
ence of persistent proteinuria or a renal structure abnor-
mality was considered to indicate CKD.13 Children were
excluded from the study if they had Stage 5 CKD at diag-
nosis, were transplant recipients, had previously received
maintenance dialysis, or were pregnant. Hypertension16 and
anemia17 were defined as previously described. The study
was approved by the Institutional Review Board of National
Cheng-Kung University Hospital (A-BR-101-082).Data extraction
We examined patient demographics, clinical characteris-
tics, CKD etiology, symptoms at diagnosis, comorbidities,
family history of disease, and disease progression as indi-
cated by an increase in CKD stage from the time of diag-
nosis to follow-up. All biochemical analyses were
performed using standard techniques. Serum creatinine
was calibrated using isotope dilution mass spectrometry. All
laboratories in Taiwan use this method to determine serum
creatinine levels, which enabled us to reliably compare
values analyzed by different laboratories.
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and for the different CKD etiologies. The specific outcomes
of interest included the relationship between eGFRs at
diagnosis and at follow-up, the percentage change in eGFR
from diagnosis to the most recent follow-up, and the spe-
cific factors associated with CKD progression.
Statistical analysis
Continuous variables with non-normal distributions were
presented as medians and interquartile ranges, and were
compared among the different CKD etiology groups using the
ManneWhitney U test. Categorical variables were presented
as counts and percentages, and were compared among CKD
etiology groups using the chi-square test or Fisher’s exact
test, as appropriate. The percentage change in eGFR was
calculated as the change in eGFR from baseline to follow-up
for Stages 1, 2, 3, and 4 of CKD and was compared among
CKD etiology groups using the KruskaleWallis test with post
hoc Bonferroni type I error adjustment.
Univariate and multivariate Cox proportional hazard
models were used to identify factors independently asso-
ciated with CKD progression for the overall cohort and
among different CKD etiology groups. The crude and
adjusted hazard ratios (HRs) and the corresponding 95%
confidence intervals (CIs) are provided. All significant fac-
tors (p < 0.05) identified in the univariate analysis were
entered in the initial multivariate analysis. The backward
selection technique was used for the final multivariate Cox
proportional hazards models, and variables that did not
improve model fit (p < 0.1) were discarded. Adjustments
were made for potential confounders such as age, gender,
and CKD etiology. The extent of multicollinearity was
evaluated by determining the variance inflation factor.
Variables with variance inflation factors of >5 were
considered to have multicollinearity with other covariates
and were excluded from the multivariate analysis.
All statistical analyses were performed using SAS soft-
ware version 9.2 (SAS Institute Inc., Cary, NC, USA). A two-
tailed p value of <0.05 indicated statistical significance.
Results
Patient selection and CKD etiologies
We identified 971 children with CKD from the TAPRC data-
base: 589 children were excluded for various reasons, and
382 children were ultimately included in the statistical
analysis; Figure 1 is a CONSORT diagram that explains pa-
tient disposition. Further, the participants’ specific CKD
etiologies were classified into two groups:
(1) structural abnormalities or genetic diseases;
(2) nephritis or hemodynamic changes (i.e., previous
history of hypovolemic or septic shock, n Z 3).
These two CKD etiology groups were approximately equal
in size: 52.1% (199 of 382) had CKD due to a structural ab-
normality or genetic disease, and 47.9% (183/382) had CKD
due to nephritis or hemodynamic changes. This roughly even
division of the two groups is atypical because the majority ofchildren with CKD had a structural abnormality or genetic
predisposition for kidney disease, which would elevate the
number of patients in thefirst group. However, the patients in
our study were Asian, and the incidence of autoimmune lupus
nephritis is significantly higher in Asians than in non-Asians,
which might contribute to the different distribution.18e21
The three most common diseases in the structural ab-
normalities or genetic diseases group were reflux ne-
phropathy (23.1%, 46/199), renal dysplasia (19.6%, 39/199),
and renal agenesis (15.6%, 31/199).
The two most common diseases or disorders in the
nephritis or hemodynamic change group were lupus
nephritis (37.2%, 68/183) and IgA nephritis (17.5%, 32/183).
We will discuss the demographic and clinical character-
istics of children with CKD and their changes in eGFR at
different stages of CKD in the following section; we will also
present univariate and multivariate analyses of factors
associated with the progression of CKD in this cohort.
Demographic and clinical characteristics of
children with CKD
Table 1 shows the demographic and clinical characteristics
of children included in the analyses, overall and by etiol-
ogy. The most common symptoms and signs at diagnosis
were abnormal renal echo, proteinuria, hematuria, and
edema. The most common comorbidities were autoimmune
disease, followed by hyperlipidemia and prematurity. The
most common familial diseases were hypertension and
diabetes mellitus. Most study participants had Stage 1 or 2
CKD (>80%), and about 14.7% of children (56 of 382)
experienced CKD progression. The median duration of
follow-up was 11.7 months.
There were many significant differences in demographic
and clinical characteristics between the two CKD etiology
groups (Table 1). In particular, compared with children who
had CKD due to nephritis or hemodynamic change, children
who had CKD due to a structural abnormality or genetic
disease were younger, were more likely to be male, had
longer follow-up, had a lower prevalence of most signs and
symptoms at diagnosis, had a lower prevalence of autoim-
mune diseases, and had lower blood pressure (p < 0.05 for
all comparisons; see Table 1 for detailed information). In
addition, patients in the structural abnormality or genetic
disease group showed a higher prevalence of organ defor-
mity, chromosome abnormality, and tumor (p < 0.05 for all
comparisons).
Changes in eGFR in children with different CKD
stages at diagnosis
Figures 2AeC show the percentage change in eGFR from
diagnosis to follow-up for children with different CKD
stages at diagnosis. Overall, for children with Stage 1, 2, 3,
or 4 CKD at baseline, the medians (interquartile ranges) of
percentage changes in eGFR were 1.80% (14.65, 6.15),
4.41% (5.48, 19.40), 2.97% (11.03, 17.26), and 0.83%
(16.92, 31.09), respectively (Figure 2A). The Krus-
kaleWallis test indicated a significant difference in the
percentage change in eGFR for children who had Stage 1
and Stage 2 CKD at baseline (p < 0.001). The findings were
Figure 1 Summary of participant selection. CKD Z chronic kidney disease; DM Z diabetes mellitus; HBV Z hepatitis B virus;
Ig Z immunoglobulin; ADPKD Z autosomal polycystic kidney disease; FSGS Z focal segmental glomerular sclerosis; MCNS Z
minimal change nephrotic syndrome; MPGN Z mebranoproliferative glomerulonephritis; Crescent GN Z crescent glomerulone-
phritis; HSP nephropathyZ Henoch-Scho¨nlein purpura nephropathy; HBV nephropathyZ hepatitis B virus-associated nephropathy;
HUS Z hemolytic uremic syndrome; DM nephropathy Z diabetic nephropathy.
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etiologies characterized as genitourinary tract or genetic
abnormalities (Figure 2B), but not for children with etiol-
ogies described as nephritis or hemodynamic changes
(Figure 2C).
When the progression of CKD was analyzed in terms of
endpoints of a 50% reduction in eGFR from baseline, 0.5%
(1/199) of patients in the structural abnormality or genetic
disease group and 4.9% (9/183) in the nephritis or hemo-
dynamic change group had a 50% reduction of eGFR from
baseline (p < 0.01). However, there were no significant
differences between the groups when analyzed by end-
points of progression of CKD 5 (2/199 vs. 4/183, pZ 0.432),
respectively.Univariate and multivariate analyses of factors
associated with CKD progression
Supplementary Table S3, and Tables 2 and 3 summarize the
findings from the univariate analyses of factors associated
with CKD progression, reporting data about the entire
cohort, structural abnormalities or genetic disease group,
and nephritis or hemodynamic change group, respectively.
In univariate analysis, anemia, comorbidities withcongenital heart disease or hyperuricemia, elevated dia-
stolic blood pressure, and CKD Stage 2 were associated with
CKD progression in the structural abnormality of the geni-
tourinary tract or genetic disease group. In addition to
anemia, comorbidity with autoimmune disease, a family
history of gout, elevated blood pressure, serum creatinine,
and blood urea nitrogen were associated with CKD in the
nephritis or hemodynamic change group. The findings from
the multivariate analysis for factors associated with CKD
progression are summarized in Table 4, according to CKD
etiology. Table 4 shows the final multivariate analysis of the
following factors: age, gender, etiology of CKD, anemia at
diagnosis, comorbidities, clinical data, and CKD stage at
baseline. Overall, after adjusting for other variables, chil-
dren with CKD due to a structural abnormality or genetic
disease had a significantly higher risk of CKD progression
compared with those who had CKD due to nephritis or he-
modynamic change (p Z 0.043). Children who had anemia
at diagnosis and elevated diastolic blood pressure and blood
urea nitrogen at baseline had a significantly increased risk
of CKD progression (p < 0.05 for all comparisons). When
Stage 2 and Stage 4 CKD were compared with Stage 1, the
results showed a decrease of the risk of progression (HR:
0.22, 95%CI: 0.10, 0.53; and HR: 0.10, 95%CI: 0.01, 0.89,
respectively).
Table 1 Demographic and clinical characteristics of children with CKD, overall and by CKD etiology (structural abnormality of
the genitourinary tract/genetic disease or nephritis/hemodynamic change).
Variable All (n Z 382) Etiology of CKD p
Structural abnormality/
genetic disease
(n Z 199)
Nephritis/hemodynamic
change (n Z 183)
Age at onset, y (n Z 382) 7.0 (1.2, 12.0) 2.3 (0.1, 8.0) 10.2 (7.0, 13.1) <0.001*
Gender, males (n Z 382) 197 (51.6) 114 (57.3) 83 (45.4) 0.026*
length of follow-up, mo (n Z 382) 11.7 (9.2, 13.1) 12.0 (10.4, 13.5) 11.0 (8.6, 12.9) 0.003*
Symptoms and signs at diagnosis
Proteinuria (n Z 351) 144 (41.0) 28 (15.5) 116 (68.2) <0.001*
Hematuria (n Z 354) 99 (28.0) 24 (13.0) 75 (44.1) <0.001*
Edema (n Z 352) 65 (18.5) 2 (1.1) 63 (37.1) <0.001*
Back pain (n Z 348) 9 (2.6) 3 (1.6) 6 (3.6) 0.318
High blood pressure (n Z 342) 36 (10.5) 3 (1.7) 33 (20.5) <0.001*
Nonspecific (n Z 355) 37 (10.4) 4 (2.2) 33 (19.4) <0.001*
Decreased urine output (n Z 350) 34 (9.7) 4 (2.2) 30 (18.1) <0.001*
Dizziness (n Z 350) 18 (5.1) 4 (2.2) 14 (8.4) 0.016*
Anemia (n Z 346) 55 (15.9) 13 (7.1) 42 (25.8) <0.001*
Increased creatinine (n Z 352) 57 (17.5) 18 (10.5) 39 (25.3) 0.001*
Renal echo abnormal (n Z 352) 185 (56.9) 134 (72.4) 51 (36.4) <0.001*
Comorbidities
Congenital heart disease (n Z 356) 10 (2.8) 8 (4.2) 2 (1.2) 0.111
Prematurity (n Z 369) 23 (6.2) 13 (6.7) 10 (5.7) 0.839
Organ deformity (n Z 356) 16 (4.5) 13 (6.9) 3 (1.8) 0.040*
Metabolic disease (n Z 369) 4 (1.1) 2 (1.0) 2 (1.1) 1.000
Tumor (n Z 368) 14 (3.8) 13 (6.7) 1 (0.6) 0.005*
Chromosome abnormality (n Z 369) 7 (1.9) 7 (3.6) 0 (0.0) 0.015*
Diabetes mellitus (n Z 369) 6 (1.6) 3 (1.6) 3 (1.7) 1.000
Autoimmune disease (n Z 368) 60 (16.3) 0 (0.0) 60 (34.3) <0.001*
Hyperuricemia (n Z 369) 15 (4.1) 5 (2.6) 10 (5.7) 0.216
Hyperlipidemia (n Z 369) 25 (6.8) 5 (2.6) 20 (11.4) 0.002*
Family history of disease
Ischemic heart disease (n Z 341) 22 (6.5) 13 (7.0) 9 (5.8) 0.825
Hypertension (n Z 352) 128 (36.4) 76 (40.0) 52 (32.1) 0.154
Cerebrovascular accident (n Z 353) 14 (4.0) 6 (3.2) 8 (4.9) 0.586
Diabetes mellitus (n Z 355) 88 (24.8) 58 (30.4) 30 (18.3) 0.012*
Hyperlipidemia (n Z 352) 8 (2.3) 5 (2.6) 3 (1.8) 0.729
Renal disease (n Z 351) 16 (4.6) 6 (3.2) 10 (6.2) 0.278
Inherited kidney disease (n Z 352) 7 (2.0) 6 (3.2) 1 (0.6) 0.127
Gout (n Z 353) 24 (6.8) 14 (7.4) 10 (6.1) 0.783
Autoimmune disease (n Z 351) 8 (2.3) 0 (0.0) 8 (4.9) 0.002*
Malignant tumor (n Z 354) 26 (7.3) 17 (8.9) 9 (5.5) 0.298
Clinical data
Age, y (n Z 382) 10.6 (6.4, 13.8) 9.2 (4.6, 13.1) 12.4 (9.0, 14.9) <0.001*
SBP, mmHg (n Z 287) 115.0 (106.0, 125.0) 112.0 (100.0, 122.0) 118.0 (110.0, 128.0) <0.001*
DBP, mmHg (n Z 287) 70.0 (60.0, 80.0) 68.0 (60.0, 75.0) 70.0 (61.0, 82.0) 0.038*
Height, cm (n Z 382) 141.0 (116.5, 157.2) 129.9 (105.2, 154.0) 150.0 (130.9, 159.8) <0.001*
Weight, kg (n Z 379) 36.7 (20.5, 51.0) 27.0 (18.0, 45.5) 42.5 (29.9, 55.0) <0.001*
BMI, kg/m2 (n Z 379) 18.1 (15.7, 21.3) 17.5 (15.2, 19.6) 19.3 (16.2, 22.4) <0.001*
eGFR, mL/min per 1.73 m2 (n Z 382) 83.6 (67.9, 102.4) 80.8 (66.7, 94.9) 87.7 (71.1, 111.9) 0.001*
Creatinine, mg/dL (n Z 382) 0.7 (0.5, 0.9) 0.7 (0.5, 0.8) 0.7 (0.5, 0.9) 0.721
BUN, mg/dL (n Z 366) 13.0 (11.0, 17.0) 13.0 (11.0, 17.0) 12.0 (10.0, 19.0) 0.273
Hb, g/dL (n Z 291) 12.8 (11.2, 14.0) 13.0 (11.8, 14.1) 12.7 (10.4, 14.0) 0.065
Hct, % (n Z 291) 37.9 (32.9, 41.2) 38.6 (35.3, 41.3) 37.0 (31.2, 40.9) 0.019*
CKD stage (n Z 382) 0.011*
Stage 1 147 (38.5) 61 (30.7) 86 (47.0)
Stage 2 169 (44.2) 101 (50.8) 68 (37.2)
Stage 3 53 (13.9) 29 (14.6) 24 (13.1)
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Table 1 (continued )
Variable All (n Z 382) Etiology of CKD p
Structural abnormality/
genetic disease
(n Z 199)
Nephritis/hemodynamic
change (n Z 183)
Stage 4 13 (3.4) 8 (4.0) 5 (2.7)
CKD progression (n Z 382) 56 (14.7) 31 (15.6) 25 (13.7) 0.597
Continuous data are presented as medians (interquartile ranges) and were compared between the CKD etiology groups by the Man-
neWhitney U test. Categorical variables are expressed as counts (percentages) and were compared between CKD etiology groups by a
chi-square test or Fisher’s exact test.
*A significant difference between the CKD etiology groups (p < 0.05).
BMIZ body mass index; BUNZ blood urea nitrogen; CKDZ chronic kidney disease; DBPZ diastolic blood pressure; eGFRZ estimated
glomerular filtration rate; Hb Z hemoglobin; Hct Z hematocrit; SBP Z systolic blood pressure.
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abnormality or genetic disease, the multivariate analysis
after adjusting for other variables showed that children
with comorbid congenital heart disease, hyperuricemia, or
Stage 1 CKD (vs. Stages 2 and 3) had a significantly
increased risk of CKD progression (Table 2, p < 0.05 for all
comparisons).
For children with CKD due to nephritis or hemodynamic
change, the multivariate analysis after adjusting for other
variables showed that male children with comorbid auto-
immune disease, and elevated systolic blood pressure and
creatinine level at baseline had a significantly increased
risk of CKD progression (Table 2, p < 0.05 for all
comparisons).Discussion
This is the first cohort study to report on the demographic
and clinical characteristics of East Asian (specifically
Taiwanese) children with CKD, and one of the few studies
to examine explicit factors associated with CKD progression
in children. Overall, the demographic and clinical charac-
teristics of children in our study were generally consistent
with the characteristics of participants in other similar
studies performed worldwide.7,8,10,11 However, the inci-
dence of anemia in our study (15.9%) was somewhat lower
than that reported by Staples et al8 and Wong et al,11 who
reported anemia rates of 37.9% and 36.6%, respectively.
The incidence of hypertension was also lower in our study
(10.5%) than in those two studies (46.9% and 50.0%,
respectively). The reason for these differences is not clear
but may be related to differences in CKD severitydmost of
our children had Stage 1 or 2 CKD, whereas children in the
Staples et al’s8 study included participants with Stages 2e4
of CKD. The different stages, along with other variables not
yet accounted for, may confound interstudy comparisons,
and one should view these observations as preliminary and
subject to further verification. With these caveats in mind,
we also note that the proportion of children who experi-
enced CKD progression in our study (14.7%) is consistent
with the findings of Staples et al,8 who found that the 1-
year progression rate was 17.3%. Again, subject to further
empirical validation, the findings from the present study
support the hypothesis that the demographic and clinicalcharacteristics of Taiwanese children with CKD perhaps are
not markedly different from those of children with CKD
throughout the world. Meta-analyses of comparable, large-
scale clinical trials in different populations or a large in-
ternational prospective clinical study will provide more
definitive data, and our preliminary results may be useful in
helping frame such studies.
Our study presented a comprehensive view of the de-
mographic and clinical characteristics of children with CKD
based on disease etiology. We identified several factors
that were associated with disease progression in the overall
population of children with CKD. Specifically, we noted an
increased rate of disease progression in children who had a
structural abnormality or genetic disease, anemia,
increased diastolic blood pressure, increased blood urea
nitrogen, or Stage 1 CKD. Several studies in children8,22,23
and one study in adults2 with CKD also found that CKD
etiology affects disease progression. Our finding that
elevated diastolic blood pressure is associated with disease
progression agrees with the well-established finding that
hypertension is associated with CKD progression in children
and adults.8,24,25 These results agree with those of previous
studies and indicate that aggressive blood-pressure control
improves renal functioning in children with CKD.25e27
Interestingly, in contrast to other studies,7,8,22 we did not
find that CKD progression was associated with age. The
relationship of hyperuricemia and CKD has been contro-
versial: Some studies have reported that hyperuricemia is
an independent risk factor of incident CKD,28,29 but other
studies showed no statistically significant relationship be-
tween hyperuricemia and incident CKD.30 Our results sup-
port the hypothesis that hyperuricemia has a significant
association with pediatric CKD progression only in patients
with a structural abnormality of the genitourinary tract or
genetic disorder. Noone and Marks31 found that 66% of their
patients had congenital structural anomalies or genetic
disease, and they also showed that hyperuricemia was
common in their CKD children and associated with renal
dysfunction, hypertension, obesity, and albuminuria. One
should note, however, that the TAPRC database allows
comparisons of only cystic and noncystic kidney diseases
and their possible effects on hyperuricemia; we did not find
significant associations and were unable to investigate po-
tential effects of renal hypoplasia, dysplasia, or unidenti-
fied renal atrophy (data not shown). Future prospective
Figure 2 Percentage change in eGFR from diagnosis to follow-up for patients with different stages of CKD at diagnosis (nZ 382).
Follow-up eGFR was determined 0.5e1.5 years after the baseline measurement for (A) all children (nZ 382), (B) children with CKD
due to structural abnormality of the genitourinary tract/genetic disease (n Z 199), and (C) children with CKD due to nephritis/
hemodynamic change (n Z 183). *A significant difference between Stages 1 and 2 (p < 0.05). CKD Z chronic kidney disease;
eGFR Z estimated glomerular filtration rate.
758 Y.-Y. Chiou et al.studies should be undertaken to further assess the role of
hyperuricemia in pediatric patients with CKD.
Interestingly, in our overall study population, anemia
was an associated risk factor for CKD progression, but it was
not a significant risk factor in any of the etiologic groups. It
has been shown that anemia correction with hematocrit
normalization following erythropoietin treatment has been
associated with accelerated renal disease progression.26,27
However, in pediatric CKD patients, increased risks for
hospitalization or death were not associated with hemato-
crit levels above 36% or 39%.32 Owing to these conflicting
reports, it is still important to conduct well-designed clin-
ical trials in the pediatric CKD population to define appro-
priate anemia management.
This study also included a comprehensive review of the
demographic and clinical characteristics of children with
CKD based on disease etiology. We identified several sig-
nificant differences in the characteristics of children in the
two etiology groups and also found that CKD etiologyinfluenced the factors associated with disease progression.
In particular, our multivariate analysis indicated that the
risk of disease progression in children with CKD due to
nephritis or hemodynamic change was elevated in children
who were male and who had an autoimmune disease,
elevated systolic blood pressure, and elevated serum
creatinine. The risk of disease progression in children with
CKD due to a structural abnormality or a genetic disease
was also elevated in children who had congenital heart
disease, hyperuricemia, and Stage 1 CKD (vs. Stage 2, 3, or
4 CKD). These findings support the hypothesis that etiology
is an important factor that should be considered in the
clinical evaluation, monitoring, and perhaps treatment of
children with CKD.
Staples et al8 demonstrated that a higher CKD stage is an
associated risk factor for the progression of CKD, which
contrasts with our results. In our structural abnormality or
genetic disease group, patients with Stage 1 CKD had higher
risk for progression. The difference probably exists because
Table 2 Univariate analysis of factors associated with CKD progression in children with CKD due to structural abnormality of
the genitourinary tract/genetic disease (n Z 199).
Factor HR (95% CI) p
Age at onset (per 1 y) (n Z 199) 1.00 (0.93, 1.08) 0.943
Gender, male (vs. female) (n Z 199) 1.07 (0.49, 2.31) 0.864
Symptoms and signs at diagnosis
Proteinuria (yes vs. no) (n Z 181) 0.70 (0.21, 2.35) 0.565
Hematuria (yes vs. no) (n Z 184) 0.73 (0.22, 2.44) 0.604
Edema (yes vs. no) (n Z 182) 3.67 (0.49, 27.53) 0.206
Back pain (yes vs. no) (n Z 183) NA 0.991
High blood pressure (yes vs. no) (n Z 181) NA 0.993
Nonspecific (yes vs. no) (n Z 185) 4.83 (0.62, 37.76) 0.133
Decreased urine output (yes vs. no) (n Z 184) NA 0.992
Dizziness (yes vs. no) (n Z 184) NA 0.991
Anemia (yes vs. no) (n Z 183) 4.24 (1.44, 12.51) 0.009*
Increased creatinine (yes vs. no) (n Z 171) 0.36 (0.05, 2.69) 0.322
Renal echo abnormal (yes vs. no) (n Z 185) 0.98 (0.39, 2.45) 0.967
Comorbidities
Congenital heart disease (yes vs. no) (n Z 189) 5.18 (1.17, 22.89) 0.030*
Prematurity (yes vs. no) (n Z 193) 1.92 (0.58, 6.38) 0.288
Organ deformity (yes vs. no) (n Z 189) 1.13 (0.27, 4.78) 0.872
Metabolic disease (yes vs. no) (n Z 193) NA 0.992
Tumor (yes vs. no) (n Z 193) 2.11 (0.72, 6.17) 0.171
Chromosome abnormality (yes vs. no) (n Z 193) 2.40 (0.56, 10.18) 0.237
Diabetes mellitus (yes vs. no) (n Z 193) NA 0.993
Autoimmune disease (yes vs. no) (n Z 193) NA NA
Hyperuricemia (yes vs. no) (n Z 193) 11.57 (2.47, 54.30) 0.002*
Hyperlipidemia (yes vs. no) (n Z 193) 2.99 (0.40, 22.37) 0.287
Family history of disease
Ischemic heart disease (yes vs. no) (n Z 186) 2.56 (0.76, 8.67) 0.130
Hypertension (yes vs. no) (n Z 190) 1.15 (0.50, 2.64) 0.739
Cerebrovascular accident (yes vs. no) (n Z 189) 3.69 (0.48, 28.25) 0.209
Diabetes mellitus (yes vs. no) (n Z 191) 0.94 (0.40, 2.17) 0.876
Hyperlipidemia (yes vs. no) (n Z 189) NA 0.990
Renal disease (yes vs. no) (n Z 189) NA 0.992
Inherited kidney diseases (yes vs. no) (n Z 188) NA 0.991
Gout (yes vs. no) (n Z 189) 0.38 (0.05, 2.82) 0.342
Autoimmune disease (yes vs. no) (n Z 189) NA NA
Malignant tumor (yes vs. no) (n Z 190) 0.58 (0.08, 4.27) 0.589
Clinical data
Age (per 1 y) (n Z 199) 1.00 (0.92, 1.08) 0.946
SBP (per 1 mmHg) (n Z 137) 1.02 (0.99, 1.04) 0.135
DBP (per 1 mmHg) (n Z 137) 1.03 (1.00, 1.06) 0.028*
Height (per 1 cm) (n Z 199) 1.00 (0.98, 1.01) 0.453
Weight (per 1 kg) (n Z 199) 1.00 (0.97, 1.02) 0.640
BMI (per 1 kg/m2) (n Z 197) 0.98 (0.88, 1.09) 0.723
eGFR (per 1 mL/min per 1.73 m2) (n Z 199) 1.01 (0.99, 1.02) 0.365
Creatinine (per 1 mg/dL) (n Z 199) 1.23 (0.62, 2.43) 0.549
BUN (per 1 mg/dL) (n Z 190) 1.01 (0.98, 1.05) 0.480
Hb (per 1 g/dL) (n Z 130) 0.84 (0.69, 1.01) 0.064
Hct (per 1%) (n Z 130) 0.95 (0.89, 1.02) 0.176
CKD stage (n Z 199)
Stage 2 (vs. Stage 1) 0.10 (0.03, 0.32) <0.001*
Stage 3 (vs. Stage 1) 0.30 (0.07, 1.27) 0.102
Stage 4 (vs. Stage 1) 0.94 (0.22, 4.03) 0.929
*A significant association with CKD progression (p < 0.05).
BMI Z body mass index; BUN Z blood urea nitrogen; CI Z confidence interval; CKD Z chronic kidney disease; DBP Z diastolic blood
pressure; eGFRZ estimated glomerular filtration rate; HbZ hemoglobin; HctZ hematocrit; HRZ hazard ratio; NAZ not applicable;
SBP Z systolic blood pressure.
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Table 3 Univariate analysis of factors associated with CKD progression in children with CKD due to nephritis/hemodynamic
change (n Z 183).
Factor HR (95% CI) p
Age at onset (per 1 y) (n Z 183) 1.08 (0.97, 1.19) 0.160
Gender, male (vs. female) (n Z 183) 1.36 (0.59, 3.11) 0.468
Symptoms and signs at diagnosis
Proteinuria (yes vs. no) (n Z 170) 0.50 (0.22, 1.16) 0.105
Hematuria (yes vs. no) (n Z 170) 0.68 (0.28, 1.65) 0.398
Edema (yes vs. no) (n Z 170) 1.28 (0.53, 3.09) 0.587
Back pain (yes vs. no) (n Z 165) 1.93 (0.25, 14.58) 0.526
High blood pressure (yes vs. no) (n Z 161) 2.44 (0.98, 6.05) 0.055
Nonspecific (yes vs. no) (n Z 170) 1.46 (0.49, 4.37) 0.498
Decreased urine output (yes vs. no) (n Z 166) 2.42 (0.88, 6.65) 0.087
Dizziness (yes vs. no) (n Z 166) 1.38 (0.32, 6.05) 0.668
Anemia (yes vs. no) (n Z 163) 2.83 (1.15, 6.99) 0.024*
Increased creatinine (yes vs. no) (n Z 154) 1.70 (0.69, 4.19) 0.246
Renal echo abnormal (yes vs. no) (n Z 140) 1.70 (0.69, 4.18) 0.250
Comorbidities
Congenital heart disease (yes vs. no) (n Z 167) NA 0.993
Prematurity (yes vs. no) (n Z 176) 0.70 (0.09, 5.20) 0.728
Organ deformity (yes vs. no) (n Z 167) NA 0.992
Metabolic disease (yes vs. no) (n Z 176) NA 0.992
Tumor (yes vs. no) (n Z 175) NA 0.994
Chromosome abnormality (yes vs. no) (n Z 176) NA NA
Diabetes mellitus (yes vs. no) (n Z 176) 1.31 (0.18, 9.82) 0.791
Autoimmune disease (yes vs. no) (n Z 175) 3.37 (1.45, 7.80) 0.005*
Hyperuricemia (yes vs. no) (n Z 176) 0.92 (0.12, 6.84) 0.935
Hyperlipidemia (yes vs. no) (n Z 176) NA 0.989
Family history of disease
Ischemic heart disease (yes vs. no) (n Z 155) 0.70 (0.09, 5.32) 0.734
Hypertension (yes vs. no) (n Z 162) 1.26 (0.53, 3.00) 0.608
Cerebrovascular accident (yes vs. no) (n Z 164) NA 0.990
Diabetes mellitus (yes vs. no) (n Z 164) 0.95 (0.36, 2.47) 0.914
Hyperlipidemia (yes vs. no) (n Z 163) NA 0.991
Renal disease (yes vs. no) (n Z 162) NA 0.991
Inherited kidney disease (yes vs. no) (n Z 164) NA 0.992
Gout (yes vs. no) (n Z 164) 3.52 (1.01, 12.29) 0.049*
Autoimmune disease (yes vs. no) (n Z 162) 1.23 (0.28, 5.31) 0.786
Malignant tumor (yes vs. no) (n Z 164) 1.59 (0.21, 12.17) 0.656
Clinical data
Age (per 1 y) (n Z 183) 1.08 (0.97, 1.21) 0.168
SBP (per 1 mmHg) (n Z 150) 1.03 (1.01, 1.05) 0.003*
DBP (per 1 mmHg) (n Z 150) 1.04 (1.01, 1.08) 0.010*
Height (per 1 cm) (n Z 183) 1.01 (0.99, 1.03) 0.439
Weight (per 1 kg) (n Z 182) 1.02 (1.00, 1.04) 0.081
BMI (per 1 kg/m2) (n Z 182) 1.06 (0.98, 1.13) 0.148
eGFR (per 1 mL/min per 1.73 m2) (n Z 183) 0.99 (0.98, 1.00) 0.058
Creatinine (per 1 mg/dL) (n Z 183) 3.47 (1.57, 7.68) 0.002*
BUN (per 1 mg/dL) (n Z 176) 1.03 (1.01, 1.05) 0.002*
Hb (per 1 g/dL) (n Z 161) 0.94 (0.80, 1.10) 0.412
Hct (per 1%) (n Z 161) 0.99 (0.94, 1.04) 0.715
CKD stage (n Z 183)
Stage 2 (vs. Stage 1) 0.80 (0.30, 2.16) 0.660
Stage 3 (vs. Stage 1) 2.18 (0.72, 6.65) 0.169
Stage 4 (vs. Stage 1) 3.89 (0.83, 18.32) 0.086
*A significant association with CKD progression (p < 0.05).
BMI Z body mass index; BUN Z blood urea nitrogen; CI Z confidence interval; CKD Z chronic kidney disease; DBP Z diastolic blood
pressure; eGFRZ estimated glomerular filtration rate; HbZ hemoglobin; HctZ hematocrit; HRZ hazard ratio; NAZ not applicable;
SBP Z systolic blood pressure.
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Table 4 Multivariate analysis of factors associated with CKD progression in children, according CKD etiology.
Factors Alla CKD due to structural abnormality of
the genitourinary tract/genetic diseaseb
CKD due to nephritis/
hemodynamic changec
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age (per 1 y) 1.08 (0.99, 1.16) 0.060 1.00 (0.91, 1.09) 0.909 1.01 (0.90, 1.13) 0.890
Gender, male (vs. female) 1.32 (0.63, 2.75) 0.460 1.57 (0.70, 3.53) 0.273 3.05 (1.13, 8.25) 0.028*
Etiology (structural abnormality/genetic
disease vs. nephritis/hemodynamic change)
2.25 (1.03, 4.94) 0.043*
Symptoms and signs at diagnosis
Anemia (yes vs. no) 3.35 (1.51, 7.41) 0.003*
Comorbidities
Congenital heart disease (yes vs. no) 16.75 (3.02, 92.94) 0.001*
Autoimmune disease (yes vs. no) 6.84 (2.37, 19.76) <0.001*
Hyperuricemia (yes vs. no) 15.62 (2.87, 85.11) 0.002*
Clinical data
SBP (per 1 mmHg) 1.03 (1.00, 1.05) 0.026*
DBP (per 1 mmHg) 1.02 (1.00, 1.05) 0.023*
BUN (per 1 mg/dL) 1.05 (1.01, 1.09) 0.010*
Creatinine (per 1 mg/dL) 4.47 (1.56, 12.84) 0.005*
CKD stage
Stage 2 (vs. Stage 1) 0.22 (0.10, 0.53) 0.001* 0.07 (0.02, 0.25) <0.001*
Stage 3 (vs. Stage 1) 0.43 (0.15, 1.20) 0.107 0.20 (0.04, 0.94) 0.041*
Stage 4 (vs. Stage 1) 0.10 (0.01, 0.89) 0.039* 0.67 (0.15, 2.99) 0.596
*A significant association with CKD progression (p < 0.05).
BUN Z blood urea nitrogen; CI Z confidence interval; CKD Z chronic kidney disease; DBP Z diastolic blood pressure; HR Z hazard ratio; SBP Z systolic blood pressure.
a n Z 272 in the final multivariate model.
b n Z 144 in the final multivariate model.
c n Z 144 in the final multivariate model.
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762 Y.-Y. Chiou et al.these kinds of patients usually have lower nephron numbers
naturally at the beginning of disease, leading to the lower
eGFR at baseline, so the progression during the early stage
may occur very soon. However, if the patients are under
suitable care, as was our cohort, the disease can be
controlled well, and the progression to later stages might
slow down, which makes a difference in the risk during
different stages. In the other group, because nephritis or
hemodynamic change destroys the normal nephron
continuously, there were no significant differences in pro-
gression between stages.33,34 Meanwhile, small fluctuations
in the GFR are common and may not indicate the true
progression if the eGFR is near the cutoff value of the
stages, so using the eGFR only for defining CKD progression
may not be perfect; more strict criteria, including other
clinical signs or importance physical values, should be
incorporated.13
Our study has several limitations. First, the TAPRC
database does not include treatment information. This may
have biased our findings and analyses to some degree.
Second, the follow-up period (0.5e1.5 years) is short, given
the nature of CKD. More analyses with longer follow-up
times are needed, particularly in view of the long-term
nature of this disease. This study reports our work to
identify etiologic factors that are germane to the longitu-
dinal development of CKD in a cohort of Taiwanese chil-
dren. These data may be of use to physicians who must
make decisions about the appropriate early care of these
patients. The authors’ work-in-progress involves longer-
term analyses and follow up, as additional data become
available from the TAPRC database. Finally, we acknowl-
edge that our sample of Taiwanese children with CKD may
not be representative of East Asia as a whole. Similar
studies are needed in China, Japan, and other Southeast
Asian countries to confirm our findings.
Despite these caveats, the results of this study suggest
that the demographic and clinical characteristics of chil-
dren with CKD from East Asia (Taiwan) are generally similar
to those of non-Asian children with CKD. Our findings also
support the hypothesis that CKD etiology is related to
certain demographic and clinical characteristics of children
with CKD. Finally, our findings indicate that several factors,
most notably anemiadand, to a lesser extent, elevated
blood pressuredare associated with the progression of
CKD. Hence, further studies may show that interventions to
treat these conditions may help delay CKD progression in
children.
Appendix A. Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.jfma.2015.07.019.References
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